Hyper-exponential growth in an epidemic model: some explicit solutions and their significance.

Publication date: Jul 17, 2026

The COVID-19 pandemic highlighted the ability of epidemics to evolve through the emergence of successive strains of greater infectiousness, which prompted the insight that hyper-exponential growth (HEG) can arise in the development of an epidemic. The phenomenon of HEG has intrigued many researchers, because of some radical differences from exponential growth such as the finite-time singularity. However, the actual mechanism of HEG was usually hidden or needed to be added phenomenologically. Thus, there was little insight into how constraints would be triggered. In this study, we explore an SIR model with evolving parameters leading to a discrete sequence of variants. This allows us to consider the HEG phenomenon in greater depth and with greater mathematical rigour. The model yields a mechanistic description of what happens at the collapse of HEG. The model also yields closed expressions for important features, such as the critical time to the singularity, in terms of basic demographic parameters. Our analysis flags a few important issues needing further research, such as the stochastic character of the emergence of variants. Greater understanding of the HEG process will yield dividends in other fields, since modern societies exhibit HEG at several levels, such as human population growth, economic indicators and technological innovation. For this reason, more research on HEG remains imperative, especially on HEG in the presence of limited resources.

Open Access PDF

Concepts Keywords
Basic Reproduction Number
Computer Simulation
COVID-19
Epidemics
Epidemiological Models
Finite-time singularity
Humans
Hyper-exponential growth
Mathematical Concepts
Models, Biological
Mutation
Pandemics
SARS-CoV-2
SIR model
Stochastic Processes
Super-exponential growth
Transmission coefficient

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH strains
disease MESH fac
disease MESH body remains
drug DRUGBANK Aspartame
disease MESH infectious diseases
disease MESH infection
disease MESH Sm1
disease MESH death
disease MESH mtc
disease MESH burn
drug DRUGBANK Ranitidine
drug DRUGBANK L-Phenylalanine
disease MESH tic
disease MESH cancer
drug DRUGBANK Cysteamine
drug DRUGBANK Sodium lauryl sulfate
disease MESH sds
drug DRUGBANK Coenzyme M
pathway REACTOME Reproduction
disease MESH included
disease MESH breast carcinomas
drug DRUGBANK Water

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *